Komori
Results4591RIBOMIC Inc.Pharmaceuticals

Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)

Although business revenue of ¥16 million was recognized in the interim period, the operating loss widened by ¥40 million, from ¥538 million in the prior-year period to ¥578 million, due to increases in research and development expenses and selling, general and administrative expenses. The full-year earnings forecast and annual dividend forecast remain unchanged.

Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
40
¥ million
Wording
Conditional
How definitive the wording is.

Results for this period

Interim period (second quarter)1 April 2026–30 September 2026Non-consolidated (individual)Japanese GAAP
Net Sales16¥ millionProgress 61.5%
Operating profit-578¥ million
Ordinary income-547¥ million
Net income attributable to owners of the parent-547¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥(9.77)
Financial position at period-end
Total assets2,636¥ million
of which net assets 2,486 ¥ millionEquity ratio 94.3%vs. prior year-end -1.1pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating-518,175
Investment+295,040
Financials+192,382
Net change-30,753

Stacked from zero: upward is an increase in cash, downward a decrease (in thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period1,896,199 thousand yen
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥26 million
Operating profit¥-1,477 million
Ordinary income¥-1,438 million
Net income¥-1,449 million
Annual Dividend Forecast0 yen and sen → 0 yen and sen
Factors Behind Changes in Business Performance

Although business revenue of ¥16 million was recognized, the operating loss was ¥578 million because research and development expenses of ¥380 million and selling, general and administrative expenses of ¥215 million were recognized. Non-operating income included ¥23 million in subsidy income from an NEDO-commissioned project, among other items, resulting in an ordinary loss of ¥547 million.

Disclosure regarding the going concern assumption

Not applicable.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Depreciation and amortization811 thousand yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End56,832,640 shares
Treasury Shares at Period-End23,824 shares
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (individual)
Period Covered1 April 2026–30 September 2026
Net Sales¥16 million
Operating profit¥-578 million
Ordinary income¥-547 million
Profit attributable to owners of the parent¥-547 million
Net income per share¥(9.77)
Equity ratioEnd of the current fiscal period 94.3 / End of previous period 95.4
Total assets¥2,636 million
Net assets¥2,486 million
Cash flows from operating activities-518,175 thousand yen
Cash flows from investing activities295,040 thousand yen
Cash flows from financing activities192,382 thousand yen
Cash and cash equivalents at end of period1,896,199 thousand yen
Full-year earnings forecastNet Sales ¥26 million / Operating profit ¥-1,477 million / Ordinary income ¥-1,438 million / Net income ¥-1,449 million
Annual Dividend Forecast0 yen and sen → 0 yen and sen
Depreciation and amortization811 thousand yen
Disclosure regarding the going concern assumptionNot applicable.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End56,832,640 shares
Treasury Shares at Period-End23,824 shares
Factors Behind Changes in Business PerformanceAlthough business revenue of ¥16 million was recognized, the operating loss was ¥578 million because research and development expenses of ¥380 million and selling, general and administrative expenses of ¥215 million were recognized. Non-operating income included ¥23 million in subsidy income from an NEDO-commissioned project, among other items, resulting in an ordinary loss of ¥547 million.
Items this document does not state (12)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Changes in the scope of consolidationMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Although business revenue of ¥16 million was recognized, an operating loss was recorded because research and development expenses of ¥380 million and selling, general and administrative expenses of ¥215 million were recognized. Ordinary loss was ¥547 million, mainly due to the recognition of ¥23 million in subsidy income from an NEDO-commissioned project.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated) | RIBOMIC Inc. (4591) timely disclosure | Komori